Human leukocyte antigen-presented viral peptide (HLA-presented viral peptide)

HLA class I/II-presented viral peptides are short viral protein fragments bound inside the peptide-binding groove of HLA molecules for cell-surface display. These complexes are recognized by T cell receptors, enabling immune detection of virus-infected (HLA I) or antigen-presenting cells (HLA II)[2][3][5]. The restriction of peptide binding is determined by both the peptide length and HLA polymorphism[1][3]. While the HLA molecules are well-characterized therapeutic and diagnostic targets, the viral peptides they present serve as immune ligands, not as druggable targets themselves. Detection and characterization of these complexes underpin vaccine and immunotherapy development, as well as diagnostics for infection and cancer[2][5][7]. Note: For therapeutic or diagnostic targeting, it is essential to refer to the HLA molecules themselves (e.g., "Human leukocyte antigen class I heavy chain") rather than the peptides presented, which are context-dependent and extremely diverse. The provided name is non-standard for molecular targeting purposes.

Other names

MHC-presented viral peptideHLA-restricted viral peptideViral T-cell epitopeViral antigenic peptideMHC ligand

Null